AbbVie and Simcere Zaiming have announced a partnership worth over $1bn to develop an investigational drug candidate for ...
In her first Ask Alex article of the year, Scientific Director, Dr Alexandra Loveday explores the ways our expert writers ...
In 2025, expect to see a continued emphasis on minimizing the environmental footprint of congress booths without compromising ...
Regeneron recently presented five-years results from the phase 3 EMPOWER-Lung 1 trial of Libtayo as a first-line treatment ...
In her latest Ask Alex article, Principal Medical Writer, Dr Alexandra Loveday explores modular content and whether it holds ...
Biogen and Eisai have announced that the US Food and Drug Administration (FDA) has accepted a Biologics License Application ...
Eli Lilly and Alchemab Therapeutics have partnered to develop new therapies for amyotrophic lateral sclerosis (ALS). The ...
In its latest update of AXS-05, Axsome reported that the 295-patient phase 3 ACCORD-2 trial met its primary endpoint, with ...
The phase 3 POETYK PsA-1 trial evaluated the drug in patients who were not previously treated with a biologic ...
Kearney Urology Center in the US has reported a 50% reduction in biopsies since adopting a new prostate cancer blood test with “unprecedented accuracy”. The test, EpiSwitch PSE, is the culmination of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback